Naftopidil tablets 25 mg for prostatic hyperplasia (Flivas, urination disorder)

General information on Japanese Naftopidil tablets 25 mg for prostatic hyperplasia (Flivas, urination disorder)

Package details: 100 tablets

Manufacturer: Nichi-Iko Pharmaceutical Co., Ltd, Japan

Active ingredient: naftopidil (chemical formula C24H28N2O3)

Medical effect: Naftopidil tablets are effective for the urination disorder associated with prostatic hypertrophy.

Contraindications and precautions: do not use for the following categories of patients:

• Patients with hepatic impairment,
• Patients with serious heart disease,
• Patients with severe cerebrovascular disease,
• Patients taking drugs with phosphodiesterase 5 inhibitory effects.

As this medicine may cause dizziness due to orthostatic hypotension, patient should pay close attention when driving a car or operating dangerous mechanisms while taking this medicine.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication, please consult with your doctor before use.

Dosage and administration

For adults: start with 1 tablet (25 mg of the active ingredient) at a time, once a day after meal. If the effect  is insufficient, gradually increase the dosage up to 2-3 tablets at a time, once a day after a meal, with an interval of 1-2 weeks between the steps. The doctor in charge may adjust the dosage according to symptoms of the patient bu the daily maximum dosage of 3 tablets (75 mg) should not be exceeded.

How effective are Naftopidil tablets 25 mg from Japan for prostatic hyperplasia (Flivas, urination disorder)?

Naftopidil is a selective alpha-1-adrenergic receptor antagonist or alpha-1 blocker. It works by blocking adrenergic alpha-1 receptors in the urethra and reducing urethral pressure. As the result, Naftopidil tablets improve urination disorder symptoms caused by enlarged prostate.

Who should take Naftopidil tablets 25 mg from Japan?

Naftopidil tablets are effective for the treatment of  male patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Studies showed that naftopidil improves urgency, urination frequency and urinary incontinence in male patients aged 50 or more in 4 weeks of treatment (T. Yokoyama, K. Uematsu et al. “Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study” // Scandinavian journal of urology and nephrology, 2009; 43(4): 307-14).